• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact

    6/22/26 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email
    • Announces new targets, including Net-Zero greenhouse gas emissions (GHG) across Scope 1 and Scope 2 by 2050 and 100% renewable electricity by 2040
    • Introduces company’s refreshed sustainability strategy, goals and governance
    • Formerly called the Corporate Responsibility Report, now published as the Sustainability Report

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company’s progress and refreshed approach to advancing a sustainable and responsible business model.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622741106/en/

    Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact

    Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact

    "As we shape Baxter’s next chapter, our focus remains clear: making a meaningful difference for patients, customers and communities while working to create long‑term value for all stakeholders," said Andrew Hider, president and chief executive officer. "The progress captured in this report is the result of the dedication of Baxter colleagues who bring our Mission to Save and Sustain Lives to life every day. Their commitment continues to drive Baxter forward and strengthen our ability to create lasting value for those we serve."

    The report highlights Baxter’s progress across key priorities in 2025, including strengthening collaboration with healthcare partners to improve patient care, driving operational efficiency and environmental sustainability, and advancing a culture of safety and well-being for employees. The company and the Baxter Foundation also continued investing in communities worldwide, including more than $32 million in contributions through strategic partnerships, product donations and employee matching gifts. Building on this progress and more than 30 years of environmental reporting, the company has refined its sustainability strategy and governance approach.

    Refreshed Sustainability Strategy and Governance

    Aligned to Baxter Growth and Performance System (GPS), which was introduced in 2025, the company strengthened its approach to sustainability governance with the establishment of its first chief sustainability officer role and newly created sustainability team, enhancing coordination and accountability across the enterprise.

    Informed by the company’s recent double materiality assessment, Baxter has refreshed both its sustainability strategy and reporting to reflect a more forward-looking approach to long-term value creation for its stakeholders. The company’s refined sustainability strategy centers on three core areas: Deliver Sustainable Healthcare, Advance Climate & Resiliency, and Champion People & Communities. The refreshed areas of focus led to a new set of targets designed to drive measurable progress, replacing the 2030 commitments previously established. New targets include:

    • Net-Zero greenhouse gas emissions (GHG) across Scope 1 and Scope 2 by 2050, aligned with a 1.5⁰ Celsius science-based target
    • 100% renewable electricity by 2040
    • 80% of supplier spend in priority categories with suppliers that have science-based targets by 2030
    • 100,000 employee volunteer hours by 2031, along with a previously established goal to invest $275 million by 2030 in underserved communities

    The sustainability strategy and goals continue to support the United Nations Sustainable Development Goals (SDG), with particular emphasis on advancing health and well‑being (SDG 3), water stewardship (SDG 6), responsible consumption (SDG 12), and climate action (SDG 13).

    "When I joined Baxter as its first chief sustainability officer, I saw firsthand a culture grounded in care, collaboration and an unwavering commitment to patients," said Renae Kezar, chief sustainability officer. "Sustainability is essential to enabling resilient healthcare delivery. Our sustainability strategy is designed to help ensure safe, reliable care while addressing the challenges facing healthcare and communities globally."

    Learn more and view the full report here.

    About Baxter

    At Baxter, we are everywhere healthcare happens – and everywhere it is going, with essential solutions in the hospital, physician’s office and other sites of care. For nearly a century, our customers have counted on us as a vital and trusted partner. And every day, millions of patients and healthcare providers rely on our unmatched portfolio of connected solutions, medical devices, and advanced injectable technologies. Approximately 37,500 Baxter team members live our enduring Mission: to Save and Sustain Lives. Together, we are redefining how care is delivered to make a greater impact today, tomorrow, and beyond. To learn more, visit www.baxter.com and follow us on X, LinkedIn and Facebook.

    This release includes forward-looking statements concerning Baxter's sustainability strategy described in the release, including newly launched sustainability targets. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company may be unable to successfully introduce or monetize new and existing products or services or keep pace with changing consumer preferences and needs or advances in technology; the company’s operating results and financial condition have fluctuated and may fluctuate in the future, which may constrain the company’s ability to achieve its financial and other goals; the company has experienced in the past and may in the future experience manufacturing, sterilization, supply, or distribution difficulties; the effects of climate change, including legal, regulatory, or market measures related to climate change and other sustainability topics, could adversely affect the company’s business, results of operations, financial condition, and cash flows; the company is subject to laws and regulations globally, and its failure to comply with rapidly changing and increasingly divergent expectations of regulators in different jurisdictions could adversely impact the company; and other risks identified in Baxter's most recent filing on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website. Baxter does not undertake to update its forward-looking statements.

    Baxter is a registered trademark of Baxter International Inc. or its subsidiaries.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260622741106/en/

    Media Contact

    Natalie Matthews, (224) 948-5353

    media@baxter.com

    Investor Contact

    Kevin Moran, (224) 507-3759

    global_corp_investor_relations@baxter.com

    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    5/28/2026$17.00Neutral → Sell
    Citigroup
    10/31/2025Buy → Hold
    Argus
    8/4/2025$25.00Buy → Hold
    Stifel
    8/1/2025$25.00Buy → Neutral
    Goldman
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact

    Announces new targets, including Net-Zero greenhouse gas emissions (GHG) across Scope 1 and Scope 2 by 2050 and 100% renewable electricity by 2040 Introduces company’s refreshed sustainability strategy, goals and governance Formerly called the Corporate Responsibility Report, now published as the Sustainability Report Baxter International Inc. (NYSE:BAX), a global medtech leader, today published its newly renamed 2025 Sustainability Report, highlighting the company’s progress and refreshed approach to advancing a sustainable and responsible business model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260622741106/en/

    6/22/26 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    MediThinQ and Synovis Micro Companies Alliance, Inc. Announce Strategic Global Distribution Agreement to Redefine Microsurgery with the SHIYA 3D Visualization Platform

    Multi-year exclusive agreement to expand access to next-generation 3D surgical visualization worldwideSEOUL, South Korea, June 18, 2026 /PRNewswire/ -- MediThinQ, a South Korea-based innovator in surgical visualization technologies, has entered into an exclusive multi-year distribution agreement with Synovis Micro Companies Alliance, Inc. ("Synovis MCA"), a subsidiary of Baxter International Inc. (NYSE:BAX) and trusted leader in microsurgical devices and solutions, to commercialize SHIYA, its 3D surgical visualization platform. Terms of this agreement were not disclosed.The agreement enables the global rollout of SHIYA through Synovis MCA, leveraging the company's deep-rooted expertise in mi

    6/18/26 10:01:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors

    Financing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D Path Board Chair 4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy, today announced the first close of a strategic financing round to accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with Biopharma companies. 4D Path's strategy is to develop digital treatment prediction biomarkers that inform more clear and accurate treatmen

    5/5/26 7:00:00 AM ET
    $BAX
    $BMRN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BAX
    SEC Filings

    View All

    SEC Form SD filed by Baxter International Inc.

    SD - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    5/29/26 8:28:26 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Baxter International Inc.

    S-8 - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    5/8/26 5:11:30 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    5/8/26 4:16:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Citigroup with a new price target

    Citigroup downgraded Baxter from Neutral to Sell and set a new price target of $17.00

    5/28/26 8:45:02 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Interim CFO, CAO & Cntrlr Zielinski Anita A was granted 13,426 shares, increasing direct ownership by 29% to 59,714 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    6/3/26 4:07:23 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    President, Adv. Surgery Wallace Steven P. covered exercise/tax liability with 153 shares, decreasing direct ownership by 0.22% to 70,128 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    6/3/26 4:06:38 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    President, CCS Teaff James covered exercise/tax liability with 321 shares, decreasing direct ownership by 1% to 31,063 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    6/3/26 4:05:30 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 5:00:53 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Baxter International Inc.

    SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 1:08:57 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Reports First-Quarter 2026 Results

    Sales from continuing operations of $2.7 billion increased 3% on a reported basis and declined 1% on an organic basis1,2 U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.03); adjusted diluted EPS from continuing operations of $0.36 Reiterates full-year 2026 financial outlook Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2026. "Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution," said Andrew Hider, president and CEO. "Although more wo

    4/30/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, April 30, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I946023356 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everyw

    4/8/26 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors

    Financing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D Path Board Chair 4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy, today announced the first close of a strategic financing round to accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with Biopharma companies. 4D Path's strategy is to develop digital treatment prediction biomarkers that inform more clear and accurate treatmen

    5/5/26 7:00:00 AM ET
    $BAX
    $BMRN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care